Laparoscopic Retroperitoneal Lymph Node Dissection: Does It Still Have a Role in the Management of Clinical Stage I Nonseminomatous Testis Cancer? A European Perspective

被引:103
|
作者
Rassweiler, Jens J. [1 ]
Scheitlin, Walter [1 ]
Heidenreich, Axel [2 ]
Laguna, M. Pilar [3 ]
Janetschek, Guenter [4 ]
机构
[1] Heidelberg Univ, Dept Urol, Klinikum Heilbronn, D-6900 Heidelberg, Germany
[2] Univ Cologne, Dept Urol, Cologne, Germany
[3] Amsterdam Med Ctr, Dept Urol, Amsterdam, Netherlands
[4] Elisabethinen Hosp Linz, Dept Urol, Linz, Austria
关键词
Testis cancer; Nonseminomatous germ cell; cancer; Retroperitoneal; lymphadenectomy; Laparoscopy; Surveillance;
D O I
10.1016/j.eururo.2008.08.022
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Laparoscopic retroperitoneal lymph node dissection (L-RPLND) is not recommended as standard tool in European Association of Urology (EAU) guidelines. Objective: To update the role of L-RPLND in patients with clinical stage I nonseminomatous germ cell tumour (NSGCT) compared to open retroperitoneal lymph node dissection (O-RPLND). Evidence acquisition: A systematic literature search from 1992 to 2008 was performed in Medline, EMBASE, and Cochrane. The largest series from each group was considered. Comparative analysis was based on raw data of series published in 2000 and later. Evidence synthesis: Results of >800 patients treated by L-RPLND reported in 34 articles were analyzed. Lymph node dissection (LND) was based on modified templates, removing an average of 16 (5-36) lymph nodes. At experienced centres, complication rates were 15.6% (9.4-25.7), including 2% (0-5) retrograde ejaculation and 1.7% (0-6) reintervention. Operating room times are longer compared to O-RPLND (204 vs 186 min). Five publications with a follow-up of 63 (36-89) mo include 557 patients, One hundred twenty-six of 140 (90%) patients with positive nodes (25%, range: 17-38) received adjuvant chemotherapy, resulting in a local relapse rate of 1.4% (0.7-2.3) with no in-field recurrence; rate of distant relapses was 3.3% (1.8-4.6), including one port-site metastasis; and rate of biochemical failure was 0.9% (0.7-2.3). Two of 14 patients with positive nodes (pN1) who did not receive adjuvant chemotherapy relapsed, both 8 mo after surgery, and were salvaged by chemotherapy. Compared with O-RPLND, there was no difference in relapse rates, percentage of patients receiving chemotherapy (29% vs 31%), chemotherapy (CTx) cycles per cohort (0.6), rate of salvage surgery (1.2% vs 1.5%), and patients with no evidence of disease (NED; 100% vs 99.7%). Conclusions: L-RPLND offers similar staging accuracy and long-term outcome to O-RPLND. In a late series of experienced L-RPLND centres, there was a trend towards fewer complications. L-RPLND represents a valuable tool for experienced laparoscopic surgeons. Further studies must focus on the curative potential of the procedure in pathologic stage IIA. (C) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1004 / 1019
页数:16
相关论文
共 50 条
  • [1] LAPAROSCOPIC RETROPERITONEAL LYMPH-NODE DISSECTION IN STAGE-A NONSEMINOMATOUS TESTIS CANCER
    STONE, NN
    SCHLUSSEL, RN
    WATERHOUSE, RL
    UNGER, P
    [J]. UROLOGY, 1993, 42 (05) : 610 - 614
  • [2] The oncological efficacy of laparoscopic retroperitoneal lymph node dissection in the treatment of clinical stage I nonseminomatous germ cell testis cancer
    Lima, G
    Nielsen, ME
    Porter, J
    Cadeddu, JA
    Tuerk, I
    Kavoussi, LR
    [J]. JOURNAL OF UROLOGY, 2006, 175 (04): : 190 - 190
  • [3] Primary laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ-cell testis tumor
    Castillo, O. A.
    Sanchez-Salas, R.
    Secin, F. P.
    Campero, J. M.
    Foneron, A.
    Vidal-Mora, I.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (01): : 22 - 28
  • [4] Morbidity of primary nerve sparing retroperitoneal lymph node dissection in clinical stage I nonseminomatous testis cancer
    Heidenreich, A
    Albers, P
    Kliesch, S
    Koehrmann, KU
    Krege, S
    Hartmann, M
    Weissbach, L
    [J]. JOURNAL OF UROLOGY, 2002, 167 (04): : 154 - 154
  • [5] Comment to: "Primary laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ-cell testis tumor"
    Alcaraz, A.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (01): : 29 - 30
  • [6] Primary laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumor
    Castillo, Octavio
    Campero, Jose M.
    Sanchez-Salas, Rafael
    Secin, Fernando P.
    Vitagliano, Gonzalo
    Diaz, Manuel
    Foneron, Alejandro
    Aranguibel, Juan C.
    [J]. JOURNAL OF UROLOGY, 2007, 177 (04): : 331 - 331
  • [7] Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors
    Abdel-Aziz, Khaled F.
    Anderson, J. Kyle
    Svatek, Robert
    Margulis, Vitaly
    Sagalowsky, Arthur I.
    Cadeddu, Jeffrey A.
    [J]. JOURNAL OF ENDOUROLOGY, 2006, 20 (09) : 627 - 631
  • [8] Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors
    Nelson, JB
    Chen, RN
    Bishoff, JT
    Oh, WK
    Kantoff, PW
    Donehower, RC
    Kavoussi, LR
    [J]. UROLOGY, 1999, 54 (06) : 1064 - 1067
  • [9] Laparoscopic Bilateral Retroperitoneal Lymph Node Dissection in Stage II Testis Cancer
    Basiri, Abbas
    Asl-Zare, Mohammad
    Sichani, Mehrdad Mohammadi
    Djaladat, Hooman
    [J]. UROLOGY JOURNAL, 2010, 7 (03) : 157 - 160
  • [10] Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer
    Albqami, N
    Janetschek, G
    [J]. JOURNAL OF ENDOUROLOGY, 2005, 19 (06) : 683 - 692